Form 4: Theravance Biopharma Director Reports Stock Transaction
Insider Transaction (Form 4)
Susannah Gray, a Director of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.
Summary
- Disposition to the issuer: disposed of 42,137 Ordinary Shares on September 23, 2026; holds 6,009 after (Direct).
- Disposition to the issuer: disposed of 6,009 Ordinary Shares on September 23, 2026 (Direct).
- Disposition to the issuer: disposed of 32,666 Share Option (Right to Buy) on September 23, 2026 (Direct).
- Disposition to the issuer: disposed of 22,044 Share Option (Right to Buy) on September 23, 2026 (Direct).
- Disposition to the issuer: disposed of 23,576 Share Option (Right to Buy) on September 23, 2026 (Direct).
- Disposition to the issuer: disposed of 24,258 Share Option (Right to Buy) on September 23, 2026 (Direct).
- Disposition to the issuer: disposed of 13,398 Share Option (Right to Buy) on September 23, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Susannah Gray — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-23 | Disposition to the issuer | Ordinary Shares | 42,137 | — | — | 6,009 |
| 2026-09-23 | Disposition to the issuer | Ordinary Shares | 6,009 | — | — | 0 |
| 2026-09-23 | Disposition to the issuer | Share Option (Right to Buy) | 32,666 | — | — | 0 |
| 2026-09-23 | Disposition to the issuer | Share Option (Right to Buy) | 22,044 | — | — | 0 |
| 2026-09-23 | Disposition to the issuer | Share Option (Right to Buy) | 23,576 | — | — | 0 |
| 2026-09-23 | Disposition to the issuer | Share Option (Right to Buy) | 24,258 | — | — | 0 |
| 2026-09-23 | Disposition to the issuer | Share Option (Right to Buy) | 13,398 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-23 | Disposition to the issuer (42,137 shares) |
| 2026-09-23 | Disposition to the issuer (6,009 shares) |
| 2026-09-23 | Disposition to the issuer (32,666 shares) |
| 2026-09-23 | Disposition to the issuer (22,044 shares) |
| 2026-09-23 | Disposition to the issuer (23,576 shares) |
| 2026-09-23 | Disposition to the issuer (24,258 shares) |
| 2026-09-23 | Disposition to the issuer (13,398 shares) |
Keywords
insider transaction, Form 4, TBPH, Theravance Biopharma, Inc., neutral, Susannah Gray
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.